Origin Genomics is advancing precision genome correction to prevent severe inherited diseases at the earliest stages of human development. The company focuses on correcting serious, well-characterized heritable conditions using precision editing tools, operating under independent IRB oversight and federal regulations. Their work aims to build the scientific and ethical foundation for safe, responsible clinical application of germline gene correction.
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Product
Problem
Families carrying devastating genetic conditions currently face limited reproductive options, including repeated IVF cycles, embryo selection, or foregoing genetically related children altogether. Existing approaches do not correct the underlying disease-causing variants, leaving carriers with difficult choices and no path to having unaffected biological children.
Solution
Origin Genomics is advancing precision genome correction to prevent severe inherited diseases at the earliest stages of human development. The company leverages the past decade's evolution of genome editing technologies, which now allow targeted correction of specific disease-causing variants with increasing fidelity. Their approach combines mature reproductive medicine and standardized embryology techniques with evolving regulatory frameworks for advanced genetic therapies. Origin Genomics operates under four core principles: pursuing correction of serious, well-characterized heritable diseases; conducting all research under independent IRB oversight and federal compliance; advancing only when safety thresholds are met; and maintaining global responsibility with principled, collaborative ethical standards.
Target Audience
Primary stakeholders are families carrying severe heritable genetic conditions, reproductive medicine researchers, and regulatory bodies governing advanced genetic therapies.
Features
- Precision genome editing tools designed to target and correct specific disease-causing variants with high fidelity
- Research programs focused exclusively on serious, well-characterized heritable diseases
- Independent IRB oversight and compliance with applicable federal and state regulations
- Safety-threshold-based progression model that advances only when data supports responsible continuation
- Ethical framework encompassing disease focus, transparency, measured progress, and global responsibility